DUBLIN, May 05, 2022--(BUSINESS WIRE)--The "Digital Marketing Trends in Rheumatoid Arthritis" report has been added to ResearchAndMarkets.com's offering.
AbbVie's Humira.com achieved the highest total traffic across RA patient sites in the US, with 7.3 million visitors from February 2021 to January 2022, followed by Pfizer's Xeljanz.com and Amgen's Enbrel.com.
The highest proportion of traffic to branded patient RA websites originated from direct sources, followed by paid. Remicade.com and Simponi.com had the highest proportion of traffic from direct search, followed by Enbrel.com.
For patient branded sites, AbbVie spent the most on DDA for Humira.com at $4.9 million, followed by AbbVie's Rinvoq.com at $3.5 million, and Pfizer's Xeljanz.com at $2.1 million.
For HCP sites, AbbVie's Humirapro.com had the highest number of total visitors, totaling around 190,000 visits from February 2021 to January 2022. The highest proportion of traffic to HCP websites in the US originated from organic and direct sources. Actemrahcp.com had the highest proportion of traffic from organic searches, followed by Remicadehcp.com.
In the US, Genentech and Sanofi were the top companies using corporate social media channels to post RA-related content. AbbVie's branded Complete Medication Tracker app for Humira and Rinvoq had the highest downloads in 2021.
In EUCAN, AbbVie is a leading player with high traffic to its country-specific branded AbbVie Care sites, as well as Janssen with its...
Read Full Story: https://finance.yahoo.com/news/digital-marketing-trends-rheumatoid-arthritis-102400131.html
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.